Steroid-containing ophthalmic solutions more likely to be contaminated

Article

Ophthalmic solutions containing steroids are 5.8 times more likely to be contaminated with bacteria than solutions that are steroid-free.

Ophthalmic solutions containing steroids are 5.8 times more likely to be contaminated with bacteria than solutions that are steroid-free, according to a report published in the October issue of the British Journal of Ophthalmology.

Danny H-Kauffmann Jokl and colleagues from the New York Medical College, New York, USA conducted a study to assess the frequency of ophthalmic solution contamination in a long-term care facility. A total of 123 solutions used for patient treatment were cultured for bacteria and the results were analysed according to the therapeutic class of the solution, how long the bottle was in use for and the appearance of the bottle upon visual inspection.

Ten (8%) of the solutions were contaminated with bacteria: four of eight steroid-containing anti-inflammatory solutions, two of six combination antimicrobial and steroid-containing anti-inflammatory solutions, two of 34 solutions for the treatment of glaucoma and two of 57 medications for dry eye. None of the mydriatic, miotic or non-combination antimicrobial solutions were found to be contaminated.

Just 30% of the contaminated bottles were considered "dirty" under visual inspection. Neither length of time that bottles had been in use or appearance of the bottles were found to be predictors of contamination.

The frequent contamination during reuse of certain steroid-containing ophthalmic solutions has led the research team to suggest that single-use solutions may be preferable.

Recent Videos
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
Sarah M. Thomasy, DVM, PhD, DACVO, a veterinary ophthalmologist at UC Davis, talks about how her research at the Glaucoma 360 symposium
I. Paul Singh, MD, an anterior segment and glaucoma specialist, discusses the Glaucoma 360 conference, where he participated in a panel discussion on the use of artificial intelligence (AI) in glaucoma care.
Charles Wykoff, MD, PhD, discusses his Floretina ICOOR presentation topic, retinal non-perfusion in diabetic retinopathy, with David Hutton, editor of Ophthalmology Times
Elizabeth Cohen, MD, discusses the Zoster Eye Disease study at the 2024 AAO meeting
Victoria L Tseng, MD, PhD, professor of ophthalmology and glaucoma specialist, UCLA
Brent Kramer, MD, of Vance Thompson Vision speaks at the 2024 AAO meeting
© 2025 MJH Life Sciences

All rights reserved.